Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAIN02
- Development stage
- Preclinical
- Lead developer
- Hangzhou Nain Biotechnology
- Modality
- Small Molecules
01
Overview
NAIN02 is a preclinical-stage small molecule developed by Hangzhou Nain Biotech that targets Organic Cation Transporter 3 (OCT3), also known as Solute Carrier Family 22 Member 3 (SLC22A3). The drug is being developed for the treatment of solid tumors. Hangzhou Nain Biotech's development platform focuses on addressing drug resistance by targeting regulated cell death (RCD) and cancer stem cells (CSC). OCT3 is a transporter involved in the uptake and efflux of various organic cations, including neurotransmitters and certain chemotherapeutic agents; its modulation is intended to influence the tumor microenvironment or overcome resistance mechanisms in solid malignancies.
02
Targets
OCT3 (Organic cation transporter 3)
Beyond the preview
Go deeper on NAIN02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAIN02.